Acura Pharmaceuticals EBIT

Acura Pharmaceuticals (ACUR) currently reports a EBIT of $-180K as of September 2023. That compares with $-630K in the prior-year period — up 71.6% year over year. That is above the sector sector average of $-9.6M. Use the charts on this page to explore Acura Pharmaceuticals's EBIT history and peer comparisons.

Acura Pharmaceuticals's EBIT increased from $-630K to $-180K — a 71.6% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Acura Pharmaceuticals's EBIT of $-180K is higher than the its sector sector average of $-9.6M. That is roughly 98.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Acura Pharmaceuticals reported $-180K in EBIT as of September 2023. That compares with $-630K in the prior-year period — up 71.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-180K, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-9.6M. From there, open related valuation or income-statement pages for Acura Pharmaceuticals, and consider following ACUR for alerts when major investors trade the stock.